Page 18 - Therapy System News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wall Street analysts predict that BioCardia, Inc. (NASDAQ:BCDA – Get Rating) will report $190,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for BioCardia’s earnings, with estimates ranging from $130,000.00 to $250,000.00. BioCardia reported sales of $70,000.00 during the same quarter last year, which indicates a positive year-over-year growth […]

BioCardia (NASDAQ:BCDA – Get Rating) had its price objective dropped by equities researchers at Maxim Group to $4.00 in a note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s target price points to a potential upside of 151.57% from the stock’s previous close. Other analysts have also issued research reports about the […]

SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and BioCardia (NASDAQ:BCDA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Analyst Ratings This is a summary of current ratings and […]

Equities analysts predict that BioCardia, Inc. (NASDAQ:BCDA – Get Rating) will announce sales of $190,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for BioCardia’s earnings, with the lowest sales estimate coming in at $130,000.00 and the highest estimate coming in at $250,000.00. BioCardia posted sales of $50,000.00 during the […]

Wall Street analysts forecast that BioCardia, Inc. (NASDAQ:BCDA – Get Rating) will report earnings per share of ($0.22) for the current quarter, according to Zacks. Two analysts have made estimates for BioCardia’s earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.33). BioCardia reported earnings per share of ($0.18) in the same quarter […]